10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q1 2019

Filing Information

Form Type	10-Q
Accession Number	`0001193125-19-134970`
Period End Date	20190331
Filing Date	20190502
Fiscal Year	2019
Fiscal Period	Q1
XBRL Instance	teva-20190331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 82 Income Statement 48 Cash Flow Statement 58 Stockholders Equity 16 Comprehensive Income 15

Balance Sheet 82 line items

Line Item	Tag	Value	Unit	Period
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.78B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.97B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.11B	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.82B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	107.00M	shares	Point-in-time
Inventories	`InventoryNet`	$4.73B	USD	Point-in-time
Inventories	`InventoryNet`	$4.78B	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$969.00M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$899.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$468.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$438.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$92.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$162.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.79B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.43B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$351.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$368.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$756.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$731.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.79B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.87B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$517.00M	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$13.19B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$14.01B	USD	Point-in-time
Goodwill	`Goodwill`	$24.92B	USD	Point-in-time
Goodwill	`Goodwill`	$24.82B	USD	Point-in-time
Total assets	`Assets`	$59.85B	USD	Point-in-time
Total assets	`Assets`	$60.68B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.22B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.79B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.20B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.71B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.76B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.85B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$870.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$633.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.87B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.87B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$804.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$773.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.03B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.32B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$2.14B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$2.08B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.67B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.73B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$25.83B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$26.70B	USD	Point-in-time
Operating Lease Liabilities	`OperatingLeaseLiabilityNoncurrent`	$424.00M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$30.00B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$30.57B	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$44.89B	USD	Point-in-time
Total liabilities	`Liabilities`	$44.03B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively	`CommonStockValue`	$56.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively	`CommonStockValue`	$56.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.21B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.23B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-5.96B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-6.06B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.36B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.46B	USD	Point-in-time
Treasury shares as of March 31, 2019 and December 31, 2018 107 million ordinary shares and 106 million ordinary shares, respectively	`TreasuryStockValue`	$4.14B	USD	Point-in-time
Treasury shares as of March 31, 2019 and December 31, 2018 107 million ordinary shares and 106 million ordinary shares, respectively	`TreasuryStockValue`	$4.14B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$14.71B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$14.73B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.09B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.09B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$20.10B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$60.68B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$59.85B	USD	Point-in-time

Income Statement 48 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.29B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.07B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.75B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.44B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.86B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.31B	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$261.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$317.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$738.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$648.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$329.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$292.00M	USD	1 Quarter
Intangible assets impairment	`IntangibleAssetsImpairments`	$206.00M	USD	1 Quarter
Intangible assets impairment	`IntangibleAssetsImpairments`	$469.00M	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$180.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$501.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$1.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-1.28B	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$57.00M	USD	1 Quarter
Other income	`OtherIncome`	$203.00M	USD	1 Quarter
Other income	`OtherIncome`	$6.00M	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$1.52B	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$134.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-218.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-271.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-84.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.25B	USD	1 Quarter
Income taxes	`IncomeTaxExpenseBenefit`	$9.00M	USD	1 Quarter
Income taxes	`IncomeTaxExpenseBenefit`	$46.00M	USD	1 Quarter
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-74.00M	USD	1 Quarter
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-4.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$1.13B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-97.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$14.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$8.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$1.12B	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-105.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-105.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$1.05B	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.10	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$1.04	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$1.03	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-0.10	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	1 Quarter

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$1.13B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-97.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$805.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$592.00M	USD	1 Quarter
Impairment of long-lived assets	`AssetImpairmentCharges`	$432.00M	USD	1 Quarter
Impairment of long-lived assets	`AssetImpairmentCharges`	$489.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$443.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$507.00M	USD	1 Quarter
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$16.00M	USD	1 Quarter
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-83.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$30.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$34.00M	USD	1 Quarter
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-33.00M	USD	1 Quarter
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-221.00M	USD	1 Quarter
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$106.00M	USD	1 Quarter
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$2.00M	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$180.00M	USD	1 Quarter
Impairment of equity investment	`ImpairmentOfInvestments`	$94.00M	USD	1 Quarter
Research and development in process	`ResearchAndDevelopmentExpense`	$54.00M	USD	1 Quarter
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$112.00M	USD	1 Quarter
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.50B	USD	1 Quarter
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$362.00M	USD	1 Quarter
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$444.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$163.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$125.00M	USD	1 Quarter
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$10.00M	USD	1 Quarter
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-23.00M	USD	1 Quarter
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$13.00M	USD	1 Quarter
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$824.00M	USD	1 Quarter
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$1.00M	USD	1 Quarter
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$56.00M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$272.00M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.04B	USD	1 Quarter
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$126.00M	USD	1 Quarter
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$6.24B	USD	1 Quarter
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	$22.00M	USD	1 Quarter
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	$52.00M	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-10.00M	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-5.00M	USD	1 Quarter
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-1.00M	USD	1 Quarter
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-261.00M	USD	1 Quarter
Proceeds from senior notes and loans, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$4.44B	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-189.00M	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.09B	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-4.00M	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.00M	USD	1 Quarter
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$455.00M	USD	1 Quarter
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$191.00M	USD	1 Quarter
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.97B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.42B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.97B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.42B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$551.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$396.00M	USD	Point-in-time

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$20.10B	USD	Point-in-time
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$1.33B	USD	1 Quarter
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-3.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$29.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$34.00M	USD	1 Quarter
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$2.00M	USD	1 Quarter
Dividends to preferred shareholders	`DividendsPreferredStockCash`	-	USD	1 Quarter
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$2.00M	USD	1 Quarter
Other	`OtherEquity`	$-6.00M	USD	1 Quarter
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$20.10B	USD	Point-in-time

Comprehensive Income 15 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$1.13B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-97.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$47.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$239.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$44.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-47.00M	USD	1 Quarter
Unrealized gain from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	1 Quarter
Total other comprehensive income	`OtherComprehensiveIncomeLossNetOfTax`	$94.00M	USD	1 Quarter
Total other comprehensive income	`OtherComprehensiveIncomeLossNetOfTax`	$196.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$1.33B	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-3.00M	USD	1 Quarter
Comprehensive income attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$97.00M	USD	1 Quarter
Comprehensive income attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$2.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$1.23B	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-5.00M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.